Search research articles
Contact Us
Filters
Showing results (111-120 of 169) with videos related to
Page
of 17
Sort By:
BMJ (Clinical Research Ed.)
|
May 31, 2012
Preventing overdiagnosis: how to stop harming the healthy
Ray Moynihan, Jenny Doust, David Henry
BMJ (Clinical Research Ed.)
|
February 9, 2020
Promises and perils of using genetic tests to predict risk of disease
Ian A Scott, John Attia, Ray Moynihan
BMJ (Clinical Research Ed.)
|
July 4, 2013
Too much medicine; too little care
Paul Glasziou, Ray Moynihan, Tessa Richards, et al.
BMJ Open
|
May 13, 2020
Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare
Ray Moynihan, Alice Fabbri, Lisa Parker, et al.
BMJ (Clinical Research Ed.)
|
June 26, 2020
Commercial influence and covid-19
Ray Moynihan, Helen Macdonald, Lisa Bero, et al.
Plos Medicine
|
July 2, 2014
Using evidence to combat overdiagnosis and overtreatment: evaluating treatments, tests, and disease definitions in the time of too much
Ray Moynihan, David Henry, Karel G M Moons
BMJ (Clinical Research Ed.)
|
May 11, 2016
"Informed choice" in a time of too much medicine-no panacea for ethical difficulties
Minna Johansson, Karsten Juhl Jørgensen, Linn Getz, et al.
BMJ (Clinical Research Ed.)
|
August 17, 2016
Authors' reply to Timms and Bird
Minna Johansson, Karsten Juhl Jørgensen, Linn Getz, et al.
BMJ (Clinical Research Ed.)
|
April 18, 2019
Commercial interests, transparency, and independence: a call for submissions
Ray Moynihan, Helen Macdonald, Carl Heneghan, et al.
The International Journal of Pharmacy Practice
|
May 6, 2010
Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme
Jane Robertson, Emily Walkom, Ray Moynihan, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 169) with videos related to
Sort By:
Page
of 17
BMJ (Clinical Research Ed.)
|
May 31, 2012
Preventing overdiagnosis: how to stop harming the healthy
Ray Moynihan, Jenny Doust, David Henry
BMJ (Clinical Research Ed.)
|
February 9, 2020
Promises and perils of using genetic tests to predict risk of disease
Ian A Scott, John Attia, Ray Moynihan
BMJ (Clinical Research Ed.)
|
July 4, 2013
Too much medicine; too little care
Paul Glasziou, Ray Moynihan, Tessa Richards, et al.
BMJ Open
|
May 13, 2020
Mixed methods evaluation of workshops for citizen health advocates about financial conflicts of interests in healthcare
Ray Moynihan, Alice Fabbri, Lisa Parker, et al.
BMJ (Clinical Research Ed.)
|
June 26, 2020
Commercial influence and covid-19
Ray Moynihan, Helen Macdonald, Lisa Bero, et al.
Plos Medicine
|
July 2, 2014
Using evidence to combat overdiagnosis and overtreatment: evaluating treatments, tests, and disease definitions in the time of too much
Ray Moynihan, David Henry, Karel G M Moons
BMJ (Clinical Research Ed.)
|
May 11, 2016
"Informed choice" in a time of too much medicine-no panacea for ethical difficulties
Minna Johansson, Karsten Juhl Jørgensen, Linn Getz, et al.
BMJ (Clinical Research Ed.)
|
August 17, 2016
Authors' reply to Timms and Bird
Minna Johansson, Karsten Juhl Jørgensen, Linn Getz, et al.
BMJ (Clinical Research Ed.)
|
April 18, 2019
Commercial interests, transparency, and independence: a call for submissions
Ray Moynihan, Helen Macdonald, Carl Heneghan, et al.
The International Journal of Pharmacy Practice
|
May 6, 2010
Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme
Jane Robertson, Emily Walkom, Ray Moynihan, et al.
Page
of 17